Answers are grounded in this paper and cite their sources.
In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: